Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...

Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a T-cell product candidate for patients with systemic lupus ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; Second Treatment Arm Adding FT819 to Maintenance Therapy without ...

Fate Therapeutics (FATE) presented new clinical and translational data from the company’s FT819 Phase 1 Autoimmunity study for ...

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...

Among the products in its pipeline is FT819, an off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate. FT819 is currently being assessed in a Phase I, multi-centre trial for individuals with ...

Included in the Company’s product candidate pipeline is FT819, the Company’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells. FT819 is currently in an ...

One of the company's notable product candidates, FT819, is currently in a Phase 1 clinical trial for patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial has so far reported ...